(410 ILCS 416/25)
Sec. 25. Reimbursement requirements; notice. (a) A reimbursement under the program at a trial site that conducts clinical trials must: (1) be reviewed and approved by the institutional review board associated with the clinical trial for which the reimbursement is provided; and (2) comply with applicable federal and State laws. (b) The independent third-party organization operating the program is not required to obtain approval from an institutional review board with respect to the financial eligibility of a subject who is medically eligible for a clinical trial. (c) The independent third-party organization operating the program shall provide written notice to a subject on: (1) the nature, availability, and scope of the ancillary financial support under the program; and (2) the program's general guidelines on financial eligibility. (Source: P.A. 103-227, eff. 6-30-23.)